Odyssey Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	0.1	2.98	4.47	1.04	-
Revenue Growth	-	-33.45%	331.24%	-	-
Cost of Revenue	120.72	121.18	112.58	112.28	101.52
Gross Profit	-120.62	-118.2	-108.11	-111.24	-101.52
Selling, General & Admin	34.21	37.52	27.12	22.2	21.02
Operating Expenses	34.21	37.52	27.12	22.2	21.02
Operating Income	-154.83	-155.72	-135.22	-133.44	-122.54
Interest Expense	-0.04	-0.02	-0.02	-0.34	-0.29
Interest & Investment Income	8.86	6.35	8.49	8.79	3.92
Currency Exchange Gain (Loss)	-	-	-	-0.16	-0.05
Other Non Operating Income (Expenses)	1.39	1.2	-0.3	-	-
EBT Excluding Unusual Items	-144.62	-148.18	-127.05	-125.14	-118.95
Gain (Loss) on Sale of Assets	-	-	-	-0.05	-
Asset Writedown	-5.44	-5.44	-	-	-
Other Unusual Items	-11.01	4.05	-1.8	-0.3	-5.13
Pretax Income	-161.07	-149.57	-128.85	-125.49	-124.32
Income Tax Expense	-1.04	-0.93	0.47	0.45	0.35
Net Income	-160.03	-148.65	-129.32	-125.94	-124.67
Preferred Dividends & Other Adjustments	-	-	1.08	4.98	-
Net Income to Common	-160.03	-148.65	-130.4	-130.92	-124.67
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	11	3	1	1	0
Shares Outstanding (Diluted)	11	3	1	1	0
Shares Change	-	267.45%	24.54%	44.71%	-
EPS (Basic)	-14.05	-50.13	-161.59	-202.04	-278.39
EPS (Diluted)	-14.05	-50.13	-161.59	-202.04	-278.39
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-132.74	-130.7	-118.24	-117.78	-112.87
Free Cash Flow Per Share	-11.65	-44.08	-146.51	-181.76	-252.05
Operating Margin	-156392.93%	-5232.39%	-3023.77%	-12867.79%	-
Profit Margin	-161643.43%	-4994.86%	-2915.94%	-12624.88%	-
Free Cash Flow Margin	-134079.80%	-4391.80%	-2643.89%	-11358.15%	-
EBITDA	-150.27	-150.81	-130.03	-128.53	-119.77
D&A For EBITDA	4.56	4.91	5.19	4.91	2.76
EBIT	-154.83	-155.72	-135.22	-133.44	-122.54

SEC Filings: 10-K · 10-Q